Becker's Healthcare February 12, 2020
Two megamergers last year faced skepticism from analysts, but both reported fourth-quarter earnings that exceeded expectations, The Wall Street Journal reported.
In June, AbbVie announced plans to acquire Allergan for $63 billion, and in November, Bristol-Myers Squibb’s $74 billion takeover of Celgene got final approval from the Federal Trade Commission.
Large deals like these are risky because the acquiring company needs to issue large amounts of debt and equity for uncertain payoff, according to the Journal.
Celgene and Allergan both faced investor concerns about patent expirations on their top-selling drugs....
Today's Sponsors
Today's Sponsor